ESPERION THERAPEUTICS INC (ESPR) Stock Price & Overview
NASDAQ:ESPR • US29664W1053
Current stock price
The current stock price of ESPR is 2.61 USD. Today ESPR is down by 0%. In the past month the price decreased by -5.78%. In the past year, price increased by 112.2%.
ESPR Key Statistics
- Market Cap
- 670.274M
- P/E
- N/A
- Fwd P/E
- 18.29
- EPS (TTM)
- -0.17
- Dividend Yield
- N/A
ESPR Stock Performance
ESPR Stock Chart
ESPR Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ESPR. When comparing the yearly performance of all stocks, ESPR is one of the better performing stocks in the market, outperforming 87.03% of all stocks.
ESPR Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ESPR. Both the profitability and financial health of ESPR have multiple concerns.
ESPR Earnings
On March 10, 2026 ESPR reported an EPS of 0.22 and a revenue of 168.45M. The company missed EPS expectations (-10.46% surprise) and missed revenue expectations (-5.37% surprise).
ESPR Forecast & Estimates
14 analysts have analysed ESPR and the average price target is 6.86 USD. This implies a price increase of 162.72% is expected in the next year compared to the current price of 2.61.
For the next year, analysts expect an EPS growth of 183.93% and a revenue growth -2.01% for ESPR
ESPR Groups
Sector & Classification
ESPR Financial Highlights
Over the last trailing twelve months ESPR reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS increased by 32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.87% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ESPR Ownership
ESPR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| ZTS | ZOETIS INC | 16.66 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ESPR
Company Profile
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Ann Arbor, Michigan and currently employs 294 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Company Info
IPO: 2013-06-24
ESPERION THERAPEUTICS INC
3891 Ranchero Drive, Suite 150, Suite 300
Ann Arbor MICHIGAN 48108 US
CEO: Tim M. Mayleben
Employees: 294
Phone: 17348873903
ESPERION THERAPEUTICS INC / ESPR FAQ
What does ESPERION THERAPEUTICS INC do?
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Ann Arbor, Michigan and currently employs 294 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Can you provide the latest stock price for ESPERION THERAPEUTICS INC?
The current stock price of ESPR is 2.61 USD.
Does ESPERION THERAPEUTICS INC pay dividends?
ESPR does not pay a dividend.
What is the ChartMill technical and fundamental rating of ESPR stock?
ESPR has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for ESPR stock?
14 analysts have analysed ESPR and the average price target is 6.86 USD. This implies a price increase of 162.72% is expected in the next year compared to the current price of 2.61.
Can you provide the sector and industry classification for ESPERION THERAPEUTICS INC?
ESPERION THERAPEUTICS INC (ESPR) operates in the Health Care sector and the Pharmaceuticals industry.
What is the next earnings date for ESPR stock?
ESPERION THERAPEUTICS INC (ESPR) will report earnings on 2026-05-04.